Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children

Why, What, and How to Undertake Estimates?

Joy E. Lawn, Fiorella Bianchi-Jassir, Neal J. Russell, Maya Kohli-Lynch, Cally J. Tann, Jennifer Hall, Lola Madrid, Carol J. Baker, Linda Bartlett, Clare Cutland, Michael G. Gravett, Paul T. Heath, Margaret Ip, Kirsty Le Doare, Shabir A. Madhi, Craig E. Rubens, Samir K. Saha, Stephanie Schrag, Ajoke Sobanjo-Ter Meulen, Johan Vekemans & 1 others Anna C. Seale

Research output: Contribution to journalArticle

Abstract

Improving maternal, newborn, and child health is central to Sustainable Development Goal targets for 2030, requiring acceleration especially to prevent 5.6 million deaths around the time of birth. Infections contribute to this burden, but etiological data are limited. Group B Streptococcus (GBS) is an important perinatal pathogen, although previously focus has been primarily on liveborn children, especially early-onset disease. In this first of an 11-article supplement, we discuss the following: (1) Why estimate the worldwide burden of GBS disease? (2) What outcomes of GBS in pregnancy should be included? (3) What data and epidemiological parameters are required? (4) What methods and models can be used to transparently estimate this burden of GBS? (5) What are the challenges with available data? and (6) How can estimates address data gaps to better inform GBS interventions including maternal immunization? We review all available GBS data worldwide, including maternal GBS colonization, risk of neonatal disease (with/without intrapartum antibiotic prophylaxis), maternal GBS disease, neonatal/infant GBS disease, and subsequent impairment, plus GBS-associated stillbirth, preterm birth, and neonatal encephalopathy. We summarize our methods for searches, meta-analyses, and modeling including a compartmental model. Our approach is consistent with the World Health Organization (WHO) Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER), published in The Lancet and the Public Library of Science (PLoS). We aim to address priority epidemiological gaps highlighted by WHO to inform potential maternal vaccination.

Original languageEnglish (US)
Pages (from-to)S89-S99
JournalClinical Infectious Diseases
Volume65
DOIs
StatePublished - Jan 1 2017

Fingerprint

Streptococcus agalactiae
Stillbirth
Pregnant Women
Infant, Newborn, Diseases
Mothers
Library Science
Antibiotic Prophylaxis
Premature Birth
Conservation of Natural Resources
Brain Diseases
Meta-Analysis
Immunization
Vaccination
Parturition
Guidelines
Pregnancy

Keywords

  • global burden
  • group B Streptococcus
  • maternal
  • neonatal
  • stillbirth

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Lawn, J. E., Bianchi-Jassir, F., Russell, N. J., Kohli-Lynch, M., Tann, C. J., Hall, J., ... Seale, A. C. (2017). Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children: Why, What, and How to Undertake Estimates? Clinical Infectious Diseases, 65, S89-S99. https://doi.org/10.1093/cid/cix653

Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children : Why, What, and How to Undertake Estimates? / Lawn, Joy E.; Bianchi-Jassir, Fiorella; Russell, Neal J.; Kohli-Lynch, Maya; Tann, Cally J.; Hall, Jennifer; Madrid, Lola; Baker, Carol J.; Bartlett, Linda; Cutland, Clare; Gravett, Michael G.; Heath, Paul T.; Ip, Margaret; Le Doare, Kirsty; Madhi, Shabir A.; Rubens, Craig E.; Saha, Samir K.; Schrag, Stephanie; Sobanjo-Ter Meulen, Ajoke; Vekemans, Johan; Seale, Anna C.

In: Clinical Infectious Diseases, Vol. 65, 01.01.2017, p. S89-S99.

Research output: Contribution to journalArticle

Lawn, JE, Bianchi-Jassir, F, Russell, NJ, Kohli-Lynch, M, Tann, CJ, Hall, J, Madrid, L, Baker, CJ, Bartlett, L, Cutland, C, Gravett, MG, Heath, PT, Ip, M, Le Doare, K, Madhi, SA, Rubens, CE, Saha, SK, Schrag, S, Sobanjo-Ter Meulen, A, Vekemans, J & Seale, AC 2017, 'Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children: Why, What, and How to Undertake Estimates?', Clinical Infectious Diseases, vol. 65, pp. S89-S99. https://doi.org/10.1093/cid/cix653
Lawn, Joy E. ; Bianchi-Jassir, Fiorella ; Russell, Neal J. ; Kohli-Lynch, Maya ; Tann, Cally J. ; Hall, Jennifer ; Madrid, Lola ; Baker, Carol J. ; Bartlett, Linda ; Cutland, Clare ; Gravett, Michael G. ; Heath, Paul T. ; Ip, Margaret ; Le Doare, Kirsty ; Madhi, Shabir A. ; Rubens, Craig E. ; Saha, Samir K. ; Schrag, Stephanie ; Sobanjo-Ter Meulen, Ajoke ; Vekemans, Johan ; Seale, Anna C. / Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children : Why, What, and How to Undertake Estimates?. In: Clinical Infectious Diseases. 2017 ; Vol. 65. pp. S89-S99.
@article{81b72e12f569445cafa2d14c54dd07e3,
title = "Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children: Why, What, and How to Undertake Estimates?",
abstract = "Improving maternal, newborn, and child health is central to Sustainable Development Goal targets for 2030, requiring acceleration especially to prevent 5.6 million deaths around the time of birth. Infections contribute to this burden, but etiological data are limited. Group B Streptococcus (GBS) is an important perinatal pathogen, although previously focus has been primarily on liveborn children, especially early-onset disease. In this first of an 11-article supplement, we discuss the following: (1) Why estimate the worldwide burden of GBS disease? (2) What outcomes of GBS in pregnancy should be included? (3) What data and epidemiological parameters are required? (4) What methods and models can be used to transparently estimate this burden of GBS? (5) What are the challenges with available data? and (6) How can estimates address data gaps to better inform GBS interventions including maternal immunization? We review all available GBS data worldwide, including maternal GBS colonization, risk of neonatal disease (with/without intrapartum antibiotic prophylaxis), maternal GBS disease, neonatal/infant GBS disease, and subsequent impairment, plus GBS-associated stillbirth, preterm birth, and neonatal encephalopathy. We summarize our methods for searches, meta-analyses, and modeling including a compartmental model. Our approach is consistent with the World Health Organization (WHO) Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER), published in The Lancet and the Public Library of Science (PLoS). We aim to address priority epidemiological gaps highlighted by WHO to inform potential maternal vaccination.",
keywords = "global burden, group B Streptococcus, maternal, neonatal, stillbirth",
author = "Lawn, {Joy E.} and Fiorella Bianchi-Jassir and Russell, {Neal J.} and Maya Kohli-Lynch and Tann, {Cally J.} and Jennifer Hall and Lola Madrid and Baker, {Carol J.} and Linda Bartlett and Clare Cutland and Gravett, {Michael G.} and Heath, {Paul T.} and Margaret Ip and {Le Doare}, Kirsty and Madhi, {Shabir A.} and Rubens, {Craig E.} and Saha, {Samir K.} and Stephanie Schrag and {Sobanjo-Ter Meulen}, Ajoke and Johan Vekemans and Seale, {Anna C.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/cid/cix653",
language = "English (US)",
volume = "65",
pages = "S89--S99",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children

T2 - Why, What, and How to Undertake Estimates?

AU - Lawn, Joy E.

AU - Bianchi-Jassir, Fiorella

AU - Russell, Neal J.

AU - Kohli-Lynch, Maya

AU - Tann, Cally J.

AU - Hall, Jennifer

AU - Madrid, Lola

AU - Baker, Carol J.

AU - Bartlett, Linda

AU - Cutland, Clare

AU - Gravett, Michael G.

AU - Heath, Paul T.

AU - Ip, Margaret

AU - Le Doare, Kirsty

AU - Madhi, Shabir A.

AU - Rubens, Craig E.

AU - Saha, Samir K.

AU - Schrag, Stephanie

AU - Sobanjo-Ter Meulen, Ajoke

AU - Vekemans, Johan

AU - Seale, Anna C.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Improving maternal, newborn, and child health is central to Sustainable Development Goal targets for 2030, requiring acceleration especially to prevent 5.6 million deaths around the time of birth. Infections contribute to this burden, but etiological data are limited. Group B Streptococcus (GBS) is an important perinatal pathogen, although previously focus has been primarily on liveborn children, especially early-onset disease. In this first of an 11-article supplement, we discuss the following: (1) Why estimate the worldwide burden of GBS disease? (2) What outcomes of GBS in pregnancy should be included? (3) What data and epidemiological parameters are required? (4) What methods and models can be used to transparently estimate this burden of GBS? (5) What are the challenges with available data? and (6) How can estimates address data gaps to better inform GBS interventions including maternal immunization? We review all available GBS data worldwide, including maternal GBS colonization, risk of neonatal disease (with/without intrapartum antibiotic prophylaxis), maternal GBS disease, neonatal/infant GBS disease, and subsequent impairment, plus GBS-associated stillbirth, preterm birth, and neonatal encephalopathy. We summarize our methods for searches, meta-analyses, and modeling including a compartmental model. Our approach is consistent with the World Health Organization (WHO) Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER), published in The Lancet and the Public Library of Science (PLoS). We aim to address priority epidemiological gaps highlighted by WHO to inform potential maternal vaccination.

AB - Improving maternal, newborn, and child health is central to Sustainable Development Goal targets for 2030, requiring acceleration especially to prevent 5.6 million deaths around the time of birth. Infections contribute to this burden, but etiological data are limited. Group B Streptococcus (GBS) is an important perinatal pathogen, although previously focus has been primarily on liveborn children, especially early-onset disease. In this first of an 11-article supplement, we discuss the following: (1) Why estimate the worldwide burden of GBS disease? (2) What outcomes of GBS in pregnancy should be included? (3) What data and epidemiological parameters are required? (4) What methods and models can be used to transparently estimate this burden of GBS? (5) What are the challenges with available data? and (6) How can estimates address data gaps to better inform GBS interventions including maternal immunization? We review all available GBS data worldwide, including maternal GBS colonization, risk of neonatal disease (with/without intrapartum antibiotic prophylaxis), maternal GBS disease, neonatal/infant GBS disease, and subsequent impairment, plus GBS-associated stillbirth, preterm birth, and neonatal encephalopathy. We summarize our methods for searches, meta-analyses, and modeling including a compartmental model. Our approach is consistent with the World Health Organization (WHO) Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER), published in The Lancet and the Public Library of Science (PLoS). We aim to address priority epidemiological gaps highlighted by WHO to inform potential maternal vaccination.

KW - global burden

KW - group B Streptococcus

KW - maternal

KW - neonatal

KW - stillbirth

UR - http://www.scopus.com/inward/record.url?scp=85034269128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034269128&partnerID=8YFLogxK

U2 - 10.1093/cid/cix653

DO - 10.1093/cid/cix653

M3 - Article

VL - 65

SP - S89-S99

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -